Company Overview and News

3
The U.S. Is Beating The World Markets By A Wide Margin

8h seekingalpha
The US stock market is beating ex-US markets by a wide margin and remains the big winner on the year.
FP SAPGF 55BC NFLX CBQS SPYR CICHY SAP SGLRF AAPL MSFT CICHF CCB XSPY 0939

14
This Is the World's Most Disappointing Stock

23h theedgemarkets
(Sept 19): For the most disappointing stock trade in the world this year, step forward Tencent Holdings Ltd.
FB BUD CCV CMCSA 55BC BC94 SMSN CCZ CBQS CICHY BABA CCV.CL 0700 AHBIF CICHF CCB CMCSK 0939 SMSD

 
Unilever and UNDP handover PPP policy paper to President’s secretary

2018-09-17 lankabusinessonline
Sept 17, 2018 (LBO) – Outlining plans to support Sri Lanka in achieving the Sustainable Development Goals, Unilever Sri Lanka and United Nations Development Programme (UNDP) handed over a policy action paper for the promotion of public private partnerships for sustainable development to the secretary to President.
DIAL SPEN 55BC CBQS

5
Public Bank among the most expensive in the region

2018-09-14 thestar.com.my
High returns: Public Bank, which is 22.8-owned by Teh, is trading at 2.45 times its book value.
HLFBF STAN PBLOF MLYNF 1295 CBQS 1023 STAB STAC SCBFF STAN UOVEF MLYBY C 55BC 1082 U11 CIMDF 1155 CGBBW 580001 UOVEY 2888 5819

 
Lynn M. Hopkins Named Chief Financial Officer of First Choice Bancorp

2018-09-13 globenewswire
Cerritos, CA, Sept. 13, 2018 (GLOBE NEWSWIRE) -- First Choice Bancorp (NASDAQ: FCBP) (“First Choice” or the “Company”) today announced that Lynn M. Hopkins has been appointed Executive Vice President and Chief Financial Officer, effective September 13, 2018. Ms. Hopkins succeeds Yvonne Chen, who will now serve as the Company’s Executive Vice President of Finance, overseeing financial planning and analysis.
FCBP 55BC PCBC PACW CBQS

24
Saudi Arabia wealth fund prepares to sign US$11bil loan

2018-09-12 thestar.com.my
DUBAI: Saudi Arabia’s sovereign wealth fund will sign an US$11bil loan this week, marking its first-ever borrowing, according to people familiar with the matter.
BGX BNPQY BGLF HSB GLSSP SCGLF STAN SCBFF MS JBK TFG SCGLY BX HCS BGB BNPZY CGBBW 2888 GLE 9984 STAN SFTBF CBQS GS STAB STAC ACA HSBC SFTBY HBCYF C GSC 55BC BNPQF CRARF GSJ 0005 580001 HSEA HSEB CRARY GJS

24
Saudi wealth fund said to prepare to sign US$11 bil loan

2018-09-12 theedgemarkets
(Sept 12): Saudi Arabia’s sovereign wealth fund will sign an US$11 billion loan this week, marking its first-ever borrowing, according to people familiar with the matter.
BGX BNPQY BGLF HSB GLSSP SCGLF STAN SCBFF MS JBK TFG SCGLY BX HCS BGB BNPZY CGBBW 2888 GLE 9984 STAN SFTBF CBQS GS STAB STAC ACA HSBC SFTBY HBCYF C GSC 55BC BNPQF CRARF GSJ 0005 580001 HSEA HSEB CRARY GJS

 
EU proposes tighter money laundering supervision but no single agency

2018-09-12 malaymail
BRUSSELS, Sept 12 — The European Commission has recommended changes to banking supervision following a series of high-profile money laundering cases but stopped short of setting up a new agency to tackle financial crime as called for by the European Central Bank.
55BC CBQS

 
Beijing is holding firm, but many Chinese firms acknowledge they're worried about the trade war

2018-09-12 cnbc
Several of China's largest companies are acknowledging that they're concerned about risks from a trade war with the U.S.
ZNH 3968 55BC CBQS 1055

 
Beijing is holding firm, but many Chinese firms acknowledge they're worried about the trade war

2018-09-12 theedgemarkets
(Sep 12): Several of China's largest companies are acknowledging that they're concerned about risks from a trade war with the U.S.
ZNH 3968 55BC CBQS 1055

 
Why Donald Trump hasn't hammered Nike over Colin Kaepernick campaign

2018-09-07 theage.com.au
Washington: As soon as the applause started during his rally in Huntsville, Alabama, a year ago, US President Donald Trump knew he had a winning issue.
55BC NYTAB CBQS

 
Why Donald Trump hasn't hammered Nike over Colin Kaepernick campaign

2018-09-07 smh.com.au
Washington: As soon as the applause started during his rally in Huntsville, Alabama, a year ago, US President Donald Trump knew he had a winning issue.
55BC NYTAB CBQS

 
China's mega banks are boasting higher profits, but investors still aren't buying their stocks

2018-09-03 cnbc
The latest earnings reports from China's big four banks showed improvements across key financial metrics, but some investors remain worried that things could get worse for lenders in the world's second-largest economy.
CICHY 55BC CBQS CICHF CCB 0939

51
Weekly Commentary: Unassailable

2018-09-02 seekingalpha
I've been here before and, candidly, it's not much fun. Lodged in my mind this week was the brilliant quote from the 19th century German philosopher Arthur Schopenhauer: "All truth passes through three stages: First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as self-evident."
BGX BGLF TWTR MS CICHF CCB BX BGB NDAQ GOOGL CGBBW TRI FB NFLX GOOG CBQS FMCKI FIG FMCKJ AAPL JEF 0939 FMCCO FMCCP FMCCM C FMCCN 55BC FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL CICHY BLK FMCC FMCCS FMCCT

 
China’s top bank ICBC first half profit up 5%

2018-08-31 thestar.com.my
SHANGHAI: Industrial and Commercial Bank of China, the world’s largest commercial bank, reported a 5% growth in first-half profit and a stable bad loan ratio.
55BC CBQS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...